These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14569846)

  • 1. Irinotecan in esophageal cancer.
    Ilson DH; Minsky B
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan, cisplatin, and radiation in esophageal cancer.
    Ilson DH; Minsky B; Kelsen D
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined modality therapy in esophageal cancer: the Memorial experience.
    Anderson SE; Minsky BD; Bains M; Kelsen DP; Ilson DH
    Semin Surg Oncol; 2003; 21(4):228-32. PubMed ID: 14648780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.
    Ajani JA; Faust J; Yao J; Komaki R; Stevens C; Swisher S; Putnam JB; Vaporciyan A; Smythe R; Walsh G; Rice D; Roth J
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):20-2. PubMed ID: 14569843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
    Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
    BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
    Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
    Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
    Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
    Lee MS; Mamon HJ; Hong TS; Choi NC; Fidias PM; Kwak EL; Meyerhardt JA; Ryan DP; Bueno R; Donahue DM; Jaklitsch MT; Lanuti M; Rattner DW; Fuchs CS; Enzinger PC
    Oncologist; 2013; 18(3):281-7. PubMed ID: 23429739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy.
    Pasini F; de Manzoni G; Pedrazzani C; Grandinetti A; Durante E; Gabbani M; Tomezzoli A; Griso C; Guglielmi A; Pelosi G; Maluta S; Cetto GL; Cordiano C
    Ann Oncol; 2005 Jul; 16(7):1133-9. PubMed ID: 15946974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
    Sun W; Whittington R; Gallagher M; O'Dwyer P; Giantonio B; Metz J; Haller D
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):39-42. PubMed ID: 15685833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan in esophageal cancer.
    Enzinger PC; Ilson DH
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):26-30. PubMed ID: 11200145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.